Fedratinib
Sign in to save this workspacePrimary targets: JAK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
96.21
Gini
0.576
CATDS
0.010
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Fedratinib. Strongest target: RET at 99.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 99.9% | 0.1% |
| 2 | JAK2 | 99.4% | 0.6% |
| 3 | FLT3 | 98.2% | 1.8% |
| 4 | ZIPK_DAPK3 | 97.7% | 2.3% |
| 5 | DAPK1 | 97.3% | 2.6% |
| 6 | SIK2 | 96.8% | 3.2% |
| 7 | DDR1 | 95.2% | 4.8% |
| 8 | FAK_PTK2 | 94.4% | 5.6% |
| 9 | JAK1 | 94.2% | 5.8% |
| 10 | TYK2 | 93.6% | 6.4% |
| 11 | ARK5_NUAK1 | 93.5% | 6.5% |
| 12 | ACK1 | 93.4% | 6.6% |
| 13 | AURORA_C | 92.1% | 7.9% |
| 14 | ROS_ROS1 | 90.7% | 9.3% |
| 15 | STK22D_TSSK1 | 90.5% | 9.5% |
| 16 | SIK1 | 88.8% | 11.2% |
| 17 | FLT4_VEGFR3 | 88.4% | 11.6% |
| 18 | DDR2 | 88.3% | 11.7% |
| 19 | LCK | 87.1% | 12.9% |
| 20 | YES_YES1 | 86.8% | 13.2% |
Selectivity landscape
Where Fedratinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Fedratinib.
Atlas insights for Fedratinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target5%
Off-target95%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 2978.90 | |
| ALLOGRAFT_REJECTION | 10006.76 | |
| ANDROGEN_RESPONSE | 1915.80 | |
| ANGIOGENESIS | 1682.91 | |
| APICAL_JUNCTION | 10132.24 | |
| APICAL_SURFACE | 1213.44 | |
| APOPTOSIS | 7716.30 | |
| BILE_ACID_METABOLISM | 1124.55 | |
| CHOLESTEROL_HOMEOSTASIS | 1384.27 | |
| COAGULATION | 1136.95 | |
| COMPLEMENT | 5578.90 | |
| DNA_REPAIR | 1869.47 | |
| E2F_TARGETS | 5241.38 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 2280.21 | |
| ESTROGEN_RESPONSE_EARLY | 3833.72 | |
| ESTROGEN_RESPONSE_LATE | 3774.63 | |
| FATTY_ACID_METABOLISM | 997.31 | |
| G2M_CHECKPOINT | 5228.55 | |
| GLYCOLYSIS | 3202.91 | |
| HEDGEHOG_SIGNALING | 1030.20 | |
| HEME_METABOLISM | 2309.14 | |
| HYPOXIA | 4407.63 | |
| IL2_STAT5_SIGNALING | 3547.81 | |
| IL6_JAK_STAT3_SIGNALING | 6918.98 | |
| INFLAMMATORY_RESPONSE | 5462.27 | |
| INTERFERON_ALPHA_RESPONSE | 1103.69 | |
| INTERFERON_GAMMA_RESPONSE | 7660.13 | |
| KRAS_SIGNALING_DN | 1224.11 | |
| KRAS_SIGNALING_UP | 3586.57 | |
| MITOTIC_SPINDLE | 6758.32 | |
| MTORC1_SIGNALING | 4157.31 | |
| MYC_TARGETS_V1 | 3633.77 | |
| MYC_TARGETS_V2 | 867.28 | |
| MYOGENESIS | 3485.24 | |
| NOTCH_SIGNALING | 141.04 | |
| OXIDATIVE_PHOSPHORYLATION | 1640.56 | |
| P53_PATHWAY | 4029.34 | |
| PANCREAS_BETA_CELLS | 290.15 | |
| PEROXISOME | 1413.67 | |
| PI3K_AKT_MTOR_SIGNALING | 10122.59 | |
| PROTEIN_SECRETION | 2192.24 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 518.19 | |
| SPERMATOGENESIS | 1732.33 | |
| TGF_BETA_SIGNALING | 2209.95 | |
| TNFA_SIGNALING_VIA_NFKB | 4941.38 | |
| UNFOLDED_PROTEIN_RESPONSE | 1835.49 | |
| UV_RESPONSE_DN | 5681.06 | |
| UV_RESPONSE_UP | 4086.88 | |
| WNT_BETA_CATENIN_SIGNALING | 2336.26 | |
| XENOBIOTIC_METABOLISM | 2349.43 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.844 |
| SRR23303752 | — | 0.836 |
| SRR10899984 | — | 0.827 |
| aMVAC.P_005_TURBT_S223 | — | 0.825 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.825 |
Annotations
Sign in to read and post annotations.
Loading…